Bristol Myers Squibb’s blockbuster cancer drug Revlimid finally has a competitor as Teva Pharmaceuticals announced the launch of a generic version of Revlimid, which could significantly cut into the global biopharmaceutical company’s earnings.

A late-stage study of Gilead Sciences’ antibody-drug conjugate Trodelvy shows promise in slowing disease progression in some of the most common forms of breast cancer.

The U.S. Food and Drug Administration placed a partial clinical hold on Alpine Immune Sciences’ NEON-2 trial, which is evaluating davoceticept (ALPN-202) in combination with Merck’s immunotherapy pembrolizumab (Keytruda) in adults with cancer.

Bristol Myers Squibb

The U.S. Food and Drug Administration approved the expanded use of Bristol Myers Squibb’s cancer drug Opdivo along with chemotherapy as treatment that patients with an aggressive form of lung cancer receive before surgery.

AbbVie

The U.S. health agency extended the review period for the expanded use of AbbVie Inc.’s psoriasis drug Skyrizi by three months, citing the need for more time to review additional data submitted by the company.

The U.S. Food and Drug Administration was reviewing the application for the use of Skyrizi in patients aged 16 years of age or older with moderate to severe Crohn’s disease, a type of inflammatory bowel disease.

The U.S. Food and Drug Administration accepted for review Pfizer Inc.’s Prior Approval Supplement to the Biologics License Application for ABRILADA (adalimumab-afzb) as an interchangeable biosimilar to Humira (adalimumab).

AbbVie

Chicago-based AbbVie has been making major decisions with company-wide impacts that could benefit its bottom line. 

Eli Lilly

The U.S. health regulator approved Eli Lilly and partner Boehringer Ingelheim’s drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure.

AstraZeneca

AstraZeneca said the company’s Enhertu cancer drug has been shown to significantly help women suffering from a type of breast cancer that leaves them with poor treatment options, opening the door to a much larger potential patient group.

Regeneron and Sanofi announced that a late-stage trial for the blockbuster anti-inflammatory drug Dupixent for patients with chronic spontaneous urticaria (CSU) was halted due to futility.